By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Galderma Laboratories LP et al. v. Actavis Mid Atlantic LLC
1:10-cv-00887; filed October 15, 2010 in the District Court of Delaware
• Plaintiffs: Galderma Laboratories LP; Galderma SA; Galderma Research and Development SNC
• Defendant: Actavis Mid Atlantic LLC
Infringement of U.S. Patent No. 7,579,377 ("Administration of 6-[3-(1-adamantyl)-4methoxyphenyl]- 2-naphthoic Acid for the Treatment of Dermatological Disorders," issued August 25, 2009) following a Paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Galderma's Differin® gel (adapalene, used in the topical treatment of acne vulgaris). View the complaint here.
Warner Chilcott Co., LLC v. Mylan Inc. et al.
1:10-cv-07840; filed October 13, 2010 in the Southern District of New York
• Plaintiff: Warner Chilcott Co., LLC
• Defendants: Mylan Inc.; Mylan Pharmaceuticals Inc.; Famy Care Ltd.
Infringement of U.S. Patent No. 6,667,050 ("Chewable Oral Contraceptive," issued December 23, 2003) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Warner Chilcott's Femcon Fe® (formerly Ovcon® 35 Fe, norethindrone and ethinyl estradiol tablets, and ferrous fumarate tablets, used for oral contraception). View the complaint here.
Purdue Pharmaceutical Products L.P. et al. v. Hospira, Inc.
1:10-cv-06471; filed October 8, 2010 in the Northern District of Illinois
• Plaintiffs: Purdue Pharmaceutical Products L.P.; Purdue Pharma L.P.; Purdue Pharma Technologies Inc.
• Defendant: Hospira, Inc.
Infringement of U.S. Patent No. 6,589,960 ("Hydromorphone And Hydrocodone Compositions And Methods For Their Synthesis," issued July 8, 2003) following a Paragraph IV certification as part of Hospira's filing of an ANDA to manufacture a generic version of Purdue Pharma's Dilaudid® (hydromorphone hydrochloride for injection, used to treat moderate to severe pain). View the complaint here.
Celgene Corp. v. Natco Pharma Ltd.
2:10-cv-05197; filed October 8, 2010 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,635,517 ("Method of Reducing TNFα Levels with Amino Substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines," issued June 3, 1997), 6,045,501 ("Methods for Delivering a Drug to a Patient While Preventing the Exposure of a Foetus or Other Contraindicated Individual to the Drug," issued April 4, 2000), 6,281,230 ("Isoindolines, Method of Use, and Pharmaceutical Compositions," issued August 28, 2001), 6,315,720 ("Methods for Delivering a Drug to a Patient While Avoiding the Occurrence of an Adverse Side Effect Known or Suspected of Being Caused by the Drug," issued November 13, 2001), 6,555,554 ("Isoindolines, Method of Use, and Pharmaceutical Compositions," issued April 29, 2003), 6,561,976 ("Methods for Delivering a Drug to a Patient While Preventing the Exposure of a Foetus or Other Contraindicated Individual to the Drug," issued May 13, 2003), 6,561,977 ("Methods for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May be Contraindicated," issued May 13, 2003), 6,755,784 (same title, issued June 29, 2004), 7,119,106 ("Pharmaceutical Compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline," issued October 10, 2006), and 7,465,800 ("Polymorphic Forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione," issued December 16, 2008) following a Paragraph IV certification as part of Natco's filing of an ANDA to manufacture a generic version of Celgene's Revlimid® (lenalidomide, used in the treatment of multiple myeloma patients who have received at least one prior therapy, and in the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality). View the complaint here.
Comments